Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1777–1781. doi: 10.1038/sj.bjc.6690283

The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck

W Anderhuber 1, W Steinschifter 2, E Schauenstein 2, A Gotschuli 1, W Habermann 1, M Fischer 2, P Felsner 3, K Schauenstein 3
PMCID: PMC2362785  PMID: 10206292

Abstract

A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera of patients with squamous cell carcinoma of the head–neck region (SCC-HN), and to evaluate its diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SCC-HN patients in post-therapeutical follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found that (i) 105 SCC-HN patients exhibited a mean value of 56.0 ± 0.7% IgG1, which likewise differed from healthy controls (63.2 ± 0.5) and benign diseases (61.5 ± 1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with post-therapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring. © 1999 Cancer Research Campaign

Keywords: squamous cell carcinoma, head-neck region tumours, tumour marker, IgG subclasses

Full Text

The Full Text of this article is available as a PDF (90.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clasen B., Roettger D., Senekowitsch R., Menz E. Squamous cell carcinoma antigen (SCC). Derzeitige klinische Wertigkeit eines neuen Tumormarkers bei Kopf-Hals-Karzinomen, Zwischenergebnisse einer prospektiven Studie nach 12 Monaten. Laryngol Rhinol Otol (Stuttg) 1988 Aug;67(8):420–425. [PubMed] [Google Scholar]
  2. Dreyfuss A. I., Clark J. R., Andersen J. W. Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck. Cancer. 1992 Nov 15;70(10):2499–2503. doi: 10.1002/1097-0142(19921115)70:10<2499::aid-cncr2820701018>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  3. Eibling D. E., Johnson J. T., Wagner R. L., Su S. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope. 1989 Feb;99(2):117–124. doi: 10.1288/00005537-198902000-00001. [DOI] [PubMed] [Google Scholar]
  4. Fischbach W., Meyer T., Barthel K. Squamous cell carcinoma antigen in the diagnosis and treatment follow-up of oral and facial squamous cell carcinoma. Cancer. 1990 Mar 15;65(6):1321–1324. doi: 10.1002/1097-0142(19900315)65:6<1321::aid-cncr2820650612>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  5. Gleich L. L., Srivastava L., Gluckman J. L. Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol. 1996 Sep;105(9):710–712. doi: 10.1177/000348949610500907. [DOI] [PubMed] [Google Scholar]
  6. Kawano Y., Noma T., Yata J. Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol. 1994 Dec 1;153(11):4948–4958. [PubMed] [Google Scholar]
  7. Koch T., Eiffert H., Spindler M. B. Die Relevanz des neuen Tumormarkers SCC (Squamous Cell Carcinoma Antigen) für die Diagnostik und Verlaufskontrolle von Plattenepithelkarzinomen im Kopf-Hals-Bereich. HNO. 1989 Nov;37(11):454–459. [PubMed] [Google Scholar]
  8. Maninger K., Weblacher M., Zatloukal K., Estelberger W., Schauenstein K., Schauenstein E. IgG1--as the only subclass of human serum IgG--spontaneously undergoes O2(-)-induced, noncovalent self-aggregation upon storage at room temperature. Free Radic Biol Med. 1996;20(3):263–270. doi: 10.1016/0891-5849(95)02030-6. [DOI] [PubMed] [Google Scholar]
  9. Maran A. G., Wilson J. A., Gaze M. N. The nature of the head and neck cancer. Eur Arch Otorhinolaryngol. 1993;250(3):127–132. doi: 10.1007/BF00171696. [DOI] [PubMed] [Google Scholar]
  10. Schauenstein E., Dachs F., Reiter M., Gombotz H., List W. Labile disulfide bonds and free thiol groups in human IgG. I. Assignment to IgG1 and IgG2 subclasses. Int Arch Allergy Appl Immunol. 1986;80(2):174–179. doi: 10.1159/000234048. [DOI] [PubMed] [Google Scholar]
  11. Schauenstein E., Lahousen M., Weblacher M., Steinschifter W., Estelberger W., Schauenstein K. Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency. Cancer. 1996 Aug 1;78(3):511–516. doi: 10.1002/(SICI)1097-0142(19960801)78:3<511::AID-CNCR19>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  12. Schauenstein E., Rabl H., Steinschifter W., Hirschmann C., Estelberger W., Schauenstein K. Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue. Cancer. 1997 Apr 15;79(8):1482–1486. [PubMed] [Google Scholar]
  13. Silverman N. A., Alexander J. C., Jr, Chretien P. B. CEA levels in head and neck cancer. Cancer. 1976 May;37(5):2204–2211. doi: 10.1002/1097-0142(197605)37:5<2204::aid-cncr2820370508>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  14. Walther E. K., Dahlmann N., Gorgulla H. T. Tumormarker bei Patienten mit Kopf-Hals-Karzinomen. Laryngorhinootologie. 1990 May;69(5):271–274. doi: 10.1055/s-2007-998188. [DOI] [PubMed] [Google Scholar]
  15. Weblacher M., Leitsberger A., Tillian H., Maninger K., Estelberger W., Schauenstein K., Schauenstein E. A decrease in reactive disulfide bonds of serum IgG signals a characteristic change in the IgG subclass patterns of rats bearing experimental tumors. Int Arch Allergy Immunol. 1993;102(4):340–346. doi: 10.1159/000236581. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES